New hope for stubborn bone pain when standard treatments fail
NCT ID NCT01791842
Summary
This study tested whether the drug tocilizumab could reduce bone pain and damage in people with fibrous dysplasia, a rare bone disorder. It focused on 19 patients who continued to have significant pain despite receiving standard bisphosphonate therapy. Researchers compared tocilizumab against a placebo to see if blocking a specific protein (IL-6) could help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Rhumatologie, Groupe Hospitalier Pellegrin
Bordeaux, France
-
Service de rhumatologie, Hopital Edouard Herriot, HCL
Lyon, 69003, France
-
Service de rhumatologie, Hôpital Lariboisière
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.